GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue.

Trial Profile

GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue.

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs Plerixafor (Primary) ; Granulocyte colony-stimulating factors
  • Indications Lymphoma; Medulloblastoma; Neuroblastoma; Sarcoma; Stem cell mobilisation
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top